Overview
Matthew Austin is a Hematologist Oncology specialist and a Hematologist in Westerly, Rhode Island. Dr. Austin is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Light Chain Deposition Disease (LCDD), MAGIC Syndrome, IgG4-Related Disease, and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections.
His clinical research consists of co-authoring 18 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Non-Small Cell Lung Cancer (NSCLC).
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE PART D
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- POS
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- MANAGED MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICAID
- STATE MEDICAID
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- EPO
- HMO
- PPO
- HMO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
25 Wells St, Westerly, RI 02891
365 Montauk Ave, Rm 2609, New London, CT 06320
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Yale University
Scott Gettinger is an Oncologist and a Hematologist in New Haven, Connecticut. Dr. Gettinger is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.
Yale University
Roy Herbst is an Oncologist in New Haven, Connecticut. Dr. Herbst is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Gamma Knife Radiosurgery.
Rhode Island Hospital
Christopher Azzoli is an Oncologist and a Hematologist in Providence, Rhode Island. Dr. Azzoli is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC).
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- ALK-Positive Non-Small Cell Lung CancerDr. Austin isExperienced. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- Bladder CancerDr. Austin isExperienced. Learn about Bladder Cancer.
- Chromophobe Renal Cell CarcinomaDr. Austin isExperienced. Learn about Chromophobe Renal Cell Carcinoma.
- Clear Cell SarcomaDr. Austin isExperienced. Learn about Clear Cell Sarcoma.
- EGFR Positive Lung CancerDr. Austin isExperienced. Learn about EGFR Positive Lung Cancer.
- Familial Prostate CancerDr. Austin isExperienced. Learn about Familial Prostate Cancer.